The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

MD Anderson and Summit Medical Group launch partnership in New Jersey

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

MD ANDERSON CANCER CENTER and Summit Medical Group in New Jersey announced the launch of their partnership to create the Summit Medical Group MD Anderson Cancer Center.

An extension of MD Anderson Cancer Center at Cooper in Camden, N.J., Summit Medical Group will now be clinically and operationally integrated with MD Anderson Cancer Center in Houston.

MD Anderson Cancer Center at Cooper joined MD Anderson Cancer Network, a program of MD Anderson Cancer Center, in 2013.

With a special emphasis on continuity of care, the new center will provide integrated, multidisciplinary cancer care for patients in northern New Jersey. The program, which provides medical oncology, infusion and diagnostic imaging, is already in place at Summit Medical Group’s campus in Berkeley Heights.

Plans are underway to build a state-of-the-art, 130,000-square-foot building adjacent to Summit Medical Group’s new facility in Florham Park, with future services to include radiation oncology. Groundbreaking is expected at the new site this summer.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account